In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 by Akihiro Takano et al.
Takano et al. EJNMMI Research 2013, 3:30
http://www.ejnmmires.com/content/3/1/30ORIGINAL RESEARCH Open AccessIn vivo TSPO imaging in patients with multiple
sclerosis: a brain PET study with [18F]FEDAA1106
Akihiro Takano1*, Fredrik Piehl2, Jan Hillert2, Andrea Varrone1, Sangram Nag1, Balázs Gulyás1, Per Stenkrona1,
Victor L Villemagne3, Christopher C Rowe3, Richard Macdonell4, Nabil Al Tawil5, Thomas Kucinski2,
Torsten Zimmermann6, Marcus Schultze-Mosgau6, Andrea Thiele6, Anja Hoffmann6† and Christer Halldin1†Abstract
Background: The activation of microglia, in general, and the upregulation of the translocator protein (18 kDa)
(TSPO) system, in particular, are key features of neuroinflammation, of which the in vivo visualization and
quantitative assessment are still challenging due to the lack of appropriate molecular imaging biomarkers. Recent
positron emission tomography (PET) studies using TSPO radioligands such as [11C]PK11195 and [11C]PBR28 have
indicated the usefulness of these PET biomarkers in patients with neuroinflammatory diseases, including multiple
sclerosis (MS). [18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO. In the
present study, we aimed at investigating the diagnostic usefulness of [18F]FEDAA1106 in patients with MS.
Methods: Nine patients (three on the interferon beta therapy and six without immunomodulatory therapy; seven
females/two males; age 34.2 ± 9.1 years old) with relapsing-remitting MS in acute relapse and with gadolinium
(Gd)-enhancing lesion(s) in the magnetic resonance imaging (MRI) scans and five healthy controls (four females/one
male, age 38.0 ± 9.7 years old) were investigated in this study. Genetic information about the TSPO binding could
not be obtained because knowledge about the importance of genetic background for TSPO binding was not
available at the time the study was performed. Dynamic PET measurements were performed using an ECAT EXACT
HR system (CTI/Siemens, Knoxville, TN, USA) for a total of 150 min, with a 30-min break after the injection of 153.4
± 10.2 MBq of [18F]FEDAA1106. Metabolite-corrected arterial plasma samples were used to calculate the input
function. PET data were analyzed in the following ways: (1) region-of-interest analysis for cortical and subcortical
regions was performed using a two-tissue compartment kinetic model in order to estimate binding potentials
(BPND) and distribution volume (VT), (2) the feasibility of the estimation of BPND and VT was investigated for MS
lesions, and (3) VT parametric images by a Logan plot and standard uptake value (SUV) images were visually
compared with the corresponding MRI, focusing on MRI-identified MS lesions.
Results: There were no significant differences in the BPND or VT values between patients with MS and healthy
controls. Robust BPND and VT values could not be obtained for most MS lesions due to noisy time-activity curves.
Visual inspection of VT and SUV images in all nine patients did not reveal high uptake of the radioligand inside and
beyond MRI-identified active MS lesions with the exception of one Gd-enhanced MS lesion in the whole patient
population.
Conclusions: In our study, [18F]FEDAA1106 as a PET radioligand could neither differentiate patients with MS from
healthy controls nor detect active plaques in the brain of MS patients. Stratification with respect to genetics and
binder status might help to uncover the differences between the groups, which could not be detected here.
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Multiple sclerosis (MS) is characterized by neuroinflam-
mation, demyelination, and axonal loss in the brain. The
activation of microglia cells is one of the main com-
ponents of neuroinflammation. The expression of the
translocator protein (TSPO) is reported to increase in
activated microglia as well as infiltrating macrophages
and reactive astrocytes in MS [1]. The evaluation of the
TSPO system may provide us with information about
the activity of the disease and its progression. Recently,
TSPO has been visualized and quantified in vivo by
positron emission tomography (PET) with various radio-
ligands. PET studies, using [11C]PK11195, have reported
increased binding in areas of focal MS lesions defined by
MRI scans, especially Gd-enhanced lesions [2]. [11C]
PBR28 displayed significantly higher white matter-gray
matter ratios in MS patients than in healthy controls as
well as increased radioligand binding in areas beyond
focal MRI-defined MS lesions [3]. [11C]vinpocetine exhi-
bited local radioligand uptakes in the vicinity of the
MRI-identified MS lesions [4].
[18F]FEDAA1106 is a recently developed PET radio-
ligand for the quantification of TSPO in vivo. Compared
with PBR28 and PK11195, FEDAA1106 has higher affinity
to TSPO (Ki = 0.078 nM) [5]. 18F radioligands have an
advantage over 11C radioligands with respect to the longer
half-life (109 vs 20 min), which makes transportation of
the ligands to PET centers, without cyclotrons, possible.
In the present study, we have investigated the diagnostic
potential of [18F]FEDAA1106 to detect MS lesions and




[18F]FEDAA1106 was synthesized, as described previously
[6]. The mean injected radioactivity was 153.4 ± 10.2
MBq. The mass injected was less than 2.7 μg.
The injection of the radioligand was performed as a
bolus over 30 s via an inserted intravenous line, and the
cannula was flushed with 10 mL of saline.
Subjects
The study was conducted in line with the Helsinki
Declaration and approved by the Independent Ethics
Committee and the Radiation Safety Committee of the
Karolinska University Hospital as well as the Swedish
Medical Products Agency. The study was registered atwww.ClinicalTrials.gov. Nine patients (seven females/two
males; age 34.2 ± 9.1 years old) with relapsing-remitting
MS in acute relapse were included in this study; six of
them were drug-naive, and three patients were on beta-
interferon treatment at the time of the PET mea-
surements. All the patients fulfilled the following criteria:
clinical signs of a relapse within a maximum of 21 days
before screening, at least two T2 lesions at different loca-
tions and at least one Gd-enhanced lesion in the MRI
screening and a score between 0 and 5 points on the
Kurtzke expanded disability status scale. Five healthy
volunteers (four females/one male, age 38.0 ± 9.7 years old)
were included in this study. Subjects who had other chronic
diseases or conditions or who used concomitant medication
that could interfere with measurements, such as treatment
with benzodiazepines, were excluded. Likewise, any un-
stable medical conditions as well as patients with either
evidence or history of a severe psychiatric disorder were
judged ineligible for this study. Healthy volunteers with
abnormal MRI findings for their ages were also excluded.
Informed written consent was obtained from all the sub-
jects. The time span between the MRI screening and the
PET scan was 3.6 ±1.4 days (1 to 6 days) for MS patients
and 9.8 ± 3.9 days (5 to 15 days) for healthy volunteers.MRI measurements
MRI T1-weighted images were acquired using the 1.5 T
GE Signa system (GE Medical Systems, Milwaukee, WI,
USA). T1-weighted, T2-weighted, and fluid-attenuated
inversion recovery (FLAIR) images were acquired for
both MS patients and healthy controls. Gd-enhanced T1
images were also acquired for MS patients.PET measurements with arterial blood sampling
PET measurements were performed on an ECAT Exact
HR 47 PET system (CTI/Siemens, Knoxville, TN, USA)
operated in 3D mode. The scanner’s three-ring detector
block architecture provides a 15-cm-wide field of view.
The transversal resolution in the reconstructed image is
about 3.8 mm full width at half maximum (FWHM), and
the axial resolution is 3.125 mm [7]. Attenuation correc-
tion was obtained with three rotating 68Ge line sources.
Emission data of [18F]FEDAA1106 were acquired over 150
min with a 30-min break between 60 and 90 min after the
radioligand injection. The frame times were 20 s × 6
frames, 1 min × 4 frames, 3 min × 6 frames, 6 min × 6
frames in the first part, and 6 min × 10 frames in the
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dard filtered back projection with a 2-mm Hanning filter.
A catheter was inserted in the radial artery, and arterial
blood was collected continuously for 5 min using an auto-
mated blood-sampling system at a speed of 5 mL/min
(ABSS; Allog AB, Mariefred, Sweden). Blood samples
(4 mL) were drawn at 2.5, 9, 20, 30, 40, 60, 90, 120, and
150 min for blood and plasma radioactivity and metabolite
correction.
Metabolite analysis
A reversed-phase high-performance liquid chromatog-
raphy (HPLC) method was used to determine the percen-
tages of radioactivity in plasma that corresponded to both
unchanged [18F]FEDAA1106 and its radioactive metabo-
lites during the course of the PET measurement. Plasma
(0.5 mL), obtained after centrifugation of blood at 2,000×g
for 2 min, was mixed with acetonitrile (0.7 mL). After
additional centrifugation of the acetonitrile-plasma mix-
ture (1.1 mL) at 2,000×g for 2 more min, the supernatant
was measured in a NaI well counter and then analyzed by
radio-HPLC.
The radio-HPLC system consisted of an interface
module (D-7000; Hitachi, Chiyoda-ku, Japan), an L-7100
pump (Hitachi), an injector (Rheodyne model 7125 with
a 1.0-mL loop; IDEX Corporation, Oak Harbor, WA,
USA), and an absorbance detector (L-7400; 254 nm;
Hitachi) in series with a radiation detector (Radiomatic
150TR; Packard, Meriden, CT, USA) equipped with a
PET flow cell (600 μL cell). A μ-Bondapak-C18 column
(300 mm × 7.8 mm, 10 μm; Waters, Milford, MA, USA)
was used for metabolite analysis. The following gradient
settings were used with a flow rate of 6.0 mL/min:
solvents - acetonitrile (A) and phosphoric acid (10 mM)
(B); time 0 min 25 (A) and 75 (B); time 4.5 min 80 (A)
and 20 (B); time 8.0 min 30 (A) and 70 (B); and time
10.0 min 25 (A) and 75 (B).
Image data analysis
Data analyses were performed focusing on the following
three main points: kinetic compartment model analysis
for brain anatomical regions, feasibility of estimation of
outcome measures for MS lesions, and visual inspection
of PET images. Group differences between patients with
MS and control subjects were intended to be investi-
gated by the evaluation of brain anatomical regions. As
Gd (+) and/or T2/FLAIR high-intensity lesions were
considered to reflect on inflammatory demyelization,
and the increase of TSPO binding was reported in such
areas in previous PET studies [2,8], the feasibility of a
quantitative evaluation of MRI-defined MS lesions was
explored. In one of the previous PET studies [3], high
TSPO binding was reported in the areas beyond the
MRI-defined MS lesions. Additionally, visual inspectionof the PET images was performed in order to detect
such changes.Kinetic analysis for brain anatomical regions
PET images of the first and second parts were core-
gistered to the T1-weighted MRI using an SPM5 soft-
ware (Wellcome Department of Imaging Neuroscience,
London, UK). Regions of interest were manually delin-
eated on the individual T1-weighted MRIs. The follow-
ing regions were defined: frontal cortex, orbitofrontal
cortex, lateral temporal cortex, insular cortex, parietal
cortex, occipital cortex, anterior cingulate cortex, poster-
ior cingulate cortex, caudate, putamen, thalamus, hippo-
campus, cerebellum, midbrain, and pons. A VOI for the
whole grey matter was obtained from the segmented
MRI. Time-activity curves for regions of interest (ROIs)
were generated by applying the ROIs to the correspon-
ding dynamic PET data.
In this study, binding potential (BPND) and total distri-
bution volume (VT), as outcome measures for [18F]
FEDAA1106 binding and brain distribution, were calcu-
lated using a two-tissue compartment (2TC) model [9].
Comparisons between patients with MS and control sub-
jects were made for BPND and VT values, respectively. In
addition, a medication-dependent stratification of the MS
group was made.Feasibility of estimation of BPND and VT for MS lesions
In the MRI brain images of MS patients, ROIs were
delineated on MRI-defined MS lesions revealed by
FLAIR and T2 and T1 Gd-enhanced scans. We focused
on the MRI-defined MS lesions of the following two
groups: Gd-enhanced MS lesions (total 49 lesions) and
non-Gd-enhanced-but-T2/FLAIR-high-intensity MS lesions
(total 159 lesions).
Time-activity curves for each MS lesion as well as for
summed subgroups were generated by applying the ROIs
to the dynamic PET data. BPND and VT were calculated
by 2TC.Visual inspection of PET images
For visual inspection of PET images, VT and standard up-
take value (SUV) images were generated. VT parametric
images were generated using the Logan plot (T* = 48 min)
[10]. SUV images were generated from the 90-to-150-min
PET images.
The parametric images were visually compared with
MRI images, focusing on MRI-defined MS lesions.
Kinetic analysis and generation of parametric images
were performed using the software package PMOD
(PMOD 3.0, PMOD Group, Zurich, Switzerland).
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Results
Kinetic analysis for brain regions
When all MS patients were compared with control
subjects, there was no significant difference of BPND or
VT in any of the evaluated regions. Furthermore, when
the MS patients were divided based on the drug treat-
ment, there was no significant difference of BPND or VT
among the three groups: MS without treatment, MS with
treatment, and normal control (Figure 1; Tables 1 and 2).
Feasibility of estimation of BPND and VT for MS lesions
The number of MS lesions detected by MRI for each
subject is shown in Table 3. The size of the largest five
MS lesions in each subject is shown in Table 3. The size
of most MS lesions determined by MRI was below 1 cm3.
BPND and VT values estimated by the 2TC model were
obtained for the five largest MS lesions of each case
(Table 4), but these values were not robust for a single
MS lesion on its own. However, even after combining all
the MS lesions of a given characteristic (Gd-enhancing
or high signal intensity in T2 and/or FLAIR) in each
subject to cover a larger area of interest, the calculated
VT and BPND of the combined regions were unrealisti-
cally high in some MS lesions and were not robustly
obtained (Table 5).
Visual inspection of PET images
Only one of the Gd-enhanced MS lesions was visually
recognized as having higher accumulation when com-
pared to other brain regions in SUV and VT images
(Figure 2).
Although some other MRI-defined MS lesions with or
without Gd-uptake may also have moderate uptake, this
uptake was not clearly higher compared to the sur-
























Figure 1 Comparison of BPND (left) and VT (right) of [
18F]FEDAA1106
(MS(−)), three with treatment (MS(+)), and five healthy controls (HC). ThereMS lesions, no obvious higher uptake of the radioligand
was detected.
Discussion
Kinetic analysis for brain regions
In the present study, we have not detected significant
differences in BPND and VT as outcome measures of
[18F]FEDAA1106 binding and brain distribution between
MS patients and healthy controls in either the whole
gray matter or in different brain regions.
There are only limited data available for the imaging
of neuroinflammation with TSPO ligands in MS patients,
and the patient populations in these studies differ signifi-
cantly, which makes interpretation and comparison
between the studies difficult. Moreover, most of the
previous studies did not focus on one clinical subtype
of MS but included different forms (e.g., relapsing-
remitting as well as secondary progressive diseases),
which might confound the results as well.
Initial data obtained with [11C]PK11195 on postmor-
tem brain tissue and in a pilot imaging study in two pa-
tients showed radioligand binding/uptake and suggested
that ligand uptake correlates with the activity of a lesion
[11]. An early study with 12 patients using [11C]
PK11195 showed some increases in focal binding in
brains of MS patients and described a certain overlap to
signal changes in the MR in single patients [1]; however,
the regional analysis in this study was limited as only the
brainstem and thalamus have been evaluated. Another
PET study with [11C]PK11195 in 22 MS patients
suggested that ligand uptake was increased in Gd-
enhancing lesions compared to normal white matter
[2]. However, this study was lacking a more detailed
comparison of different brain regions. A more recent
PET study using [11C]PBR28 as TSPO ligand could not






















in whole gray matter among MS patients. Six without treatment
were no significant differences of BPND or VT.
Table 1 Regional BPND values among MS patients and healthy controls
Region Six MS naive Three MS treatment (+) Five HC
Mean Min Max Mean Min Max Mean Min Max
Whole gray matter 4.1 3.2 5.3 3.7 2.8 5.0 4.9 2.4 8.9
ACC 4.5 2.7 7.1 3.4 2.1 5.5 5.8 2.5 13.5
Caudate 3.7 2.1 4.7 3.5 2.7 4.8 5.1 2.1 9.5
Putamen 4.1 3.2 5.2 3.6 2.2 4.9 4.3 2.1 8.2
Thalamus 4.5 3.4 5.9 5.2 2.8 8.8 6.1 2.4 13.9
Cerebellum 4.2 3.2 5.1 3.7 2.9 4.9 4.9 2.4 9.1
Frontal cortex 4.2 3.3 5.6 4.0 2.9 5.4 5.1 2.6 8.9
Hippocampus 4.5 3.1 6.9 5.1 2.0 9.2 5.2 3.1 9.8
Insular cortex 4.0 3.2 4.9 4.1 2.9 5.3 4.6 2.2 8.5
Lateral temporal cortex 4.3 3.1 5.6 3.9 2.9 5.0 5.1 2.7 9.4
Midbrain 6.4 3.0 14.0 6.6 2.5 13.0 5.5 2.9 11.7
Occipital cortex 3.8 3.0 4.6 3.4 2.5 4.5 4.4 2.5 7.0
Orbitofrontal cortex 5.4 3.2 12.2 4.0 2.8 5.3 5.1 2.8 9.1
Parietal cortex 4.0 3.2 5.2 3.7 2.9 4.5 4.7 2.6 7.7
PCC 4.3 2.5 6.3 4.4 2.4 8.0 5.4 2.7 8.4
Pons 4.5 3.4 6.0 4.4 2.4 8.0 6.0 3.9 11.7
There was no significant difference of the BPND values in any region among the three groups.
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MS patients. However, contrast-enhancing lesions did
show a significantly higher [11C]PBR28 binding com-
pared to contralateral NAWM [3].
Although our study focused on relapsing-remitting
MS only and specifically aimed at Gd-enhancing lesions,Table 2 Regional VT values among MS patients and healthy c
Region Six MS naive
Mean Min Max Mea
Whole gray matter 14.0 11.8 17.2 10.
ACC 14.8 11.5 19.2 9.7
Caudate 12.8 10.5 16.2 10.
Putamen 14.7 12.0 18.6 9.4
Thalamus 15.3 13.2 20.6 13.
Cerebellum 14.9 12.6 17.6 10.
Frontal cortex 14.9 12.9 17.2 10.
Hippocampus 12.8 10.1 14.5 12.
Insular cortex 14.1 12.3 19.0 10.
Lateral temporal cortex 14.2 11.8 17.6 9.8
Midbrain 14.4 9.7 22.4 11.
Occipital cortex 14.6 11.9 18.6 10.
Orbitofrontal cortex 19.4 12.0 44.5 10.
Parietal cortex 14.4 12.4 18.2 9.8
PCC 16.2 12.7 25.2 11.
Pons 13.7 11.3 17.7 18.
There was no significant difference of the VT values in any region among the threeusing [18F]FEDAA1106 as a new TSPO ligand, we were
not able to reproduce these earlier results. This might be
due to the specific features of [18F]FEDAA1106, which
we will discuss in the following in further detail.
The time-activity curves of [18F]FEDAA1106 showed
slower kinetics in the white matter than in the grayontrols
Three MS treatment (+) Five HC
n Min Max Mean Min Max
1 7.8 13.8 14.0 7.2 17.8
7.3 14.4 13.8 5.9 19.4
2 8.0 14.1 13.5 7.5 17.3
7.8 12.0 13.5 8.1 16.9
3 9.5 20.3 15.9 6.4 19.3
5 8.4 14.3 14.1 7.4 18.6
7 8.1 14.6 14.7 7.3 19.1
1 7.3 21.1 11.5 6.2 14.0
7 8.3 14.2 13.9 7.2 19.8
8.1 13.0 14.1 7.4 17.8
0 7.3 18.0 10.9 6.6 13.8
1 7.4 13.1 14.5 8.0 18.8
8 8.3 14.5 14.7 7.8 20.2
7.4 13.3 14.1 7.2 18.5
9 8.0 19.6 15.8 8.4 23.2
0 7.9 38.0 12.9 10.2 15.6
groups.
Table 3 Number of MS lesions and sizes of the 5 largest MS lesions in each subject
Subject Number of MS lesions Gd(+) Sizes of five largest MS plaques (cm3)
Total number T2 and/or FLAIR high MSL1 MSL2 MSL3 MSL4 MSL5
A 14 13 2 0.3 0.2 0.1 0.1a 0.1
B 20 18 6 6.2 4.3 2.9 1.6 0.7
C 42 42 4 1.3a 1.2 1.1 1.0 0.8
D 25 25 3 0.8 0.6 0.6 0.6 0.5
E 31 31 20 0.6 0.6 0.4 0.4 0.2a
F 29 29 3 15 4.0 1.7 1.6 1.5
G 10 10 5 10 1.8 0.2a 0.1 0.1
H 30 30 3 0.7 0.4 0.4 0.3a 0.2
I 10 10 2 0.7a 0.3 0.2 0.1 0.1
aGd-enhanced MS lesions. Other values were MS lesions which showed T2 and/or FLAIR high intensity but not Gd-enhanced MS lesions. As some MS lesions show
both Gd-enhanced and T2 and/or FLAIR high intensity, the total number of MS lesions is not the sum of T2 and/or FLAIR high-intensity lesions and
Gd-enhanced lesions.
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time (up to 150 min) in some subjects (data not shown).
Due to this, the 2TC model did not converge well.
Therefore, white matter might not be an appropriate
region for data evaluation using a 2TC model with [18F]
FEDAA1106.
Another reason possibly obscuring a potential differ-
ence of TSPO binding between patients with MS and
healthy controls is the ‘non-binder’ issue for TSPO
imaging. ‘Non-binders’ have been reported for [11C]
PBR28 in one out of ten subjects [12]. They showed only
very low binding to TSPO. It is reported that there are
three different affinity states (high, mixed, and low) for
TSPO binding, and it is only recently discovered that
genetic polymorphism underlies the binder - non-binder
difference [13]. The importance of evaluation of TSPO
polymorphisms has been emphasized recently [14-16].
The phenomenon is considered to be common for the
newer TSPO radioligands with [11C]PK11195 probably
being the only exception. Although the existence of
different binding states has not been reported for [18F]Table 4 BPND and VT values for the five largest MS lesions in
Subject BPND
MSL1 MSL2 MSL3 MSL4 MS
A - 1.0 - 5.0a 4.2
B 8.2 3.9 5.5 15.7 6.4
C 2.4a 14.1 5.7 4.2 9.0
D 4.3 - 9.3 - 3.3
E 24.5 - 12.8 9.7 7.9
F 26.9 17.2 3.4 19.4 -
G 4.7 7.7 15.4a 0.3 -
H 5.0 - 15.9 26.3a 5.4
I 12.0a 4.0 27.3 16.8 4.0
aGd-enhanced MS lesions. Other values were MS lesions which showed T2 and/or FFEDAA1106 yet, it has been reported for [11C]DAA1106
[17]. As FEDAA1106 has a similar chemical structure to
that of DAA1106, FEDAA1106 is likely to show similar
properties and probably will exhibit different binding
states as like all newer TSPO ligands including PBR28.
There is approximately a 50-fold difference between
high and low affinity binders for PBR28 causing the
phenomenon of non-binders. For DAA1106, DPA713,
and PBR111, the difference between high- and low-affinity
binders is about fivefold. The extent of differences
between high- and low-affinity binders for FEDAA1106,
and its relative impact awaits further study. This informa-
tion was not available at the time this study was
conducted. In future studies, checking the binding state
will allow subjects to be stratified into different binding
status groups, which might help detect the group differ-
ences between patients and healthy controls.
Feasibility of estimation of BPND and VT for MS lesions
BPND and VT calculated by a 2TC model were not able to
quantitatively characterize MS lesions. Previous studies9 MS patients
VT
L5 MSL1 MSL2 MSL3 MSL4 MSL5
- 1.6 - 17.1a 4.4
15.1 10.6 11.8 13.7 11.1
12.6a 9.4 10.2 15.9 4.8
7.1 - 5.5 - 6.8
a 7.2 - 19.7 11.9 10.2a
22.9 15.1 8.8 16.5 -
11.3 11.6 32.4a 8.6 -
7.0 6.6 37.5 12.0a 5.5
35.6a 30.8 4.6 21.6 6.6
LAIR high intensity but not Gd-enhanced MS lesions.
Table 5 BPND and VT values of the combined regions in 9
MS patients
Subject BPND VT
Gd (+) T2 and/or
FLAIR high
Gd (+) T2 and/or
FLAIR high
A 12.7 2.6 34.4 4.9
B 26.6 5.7 28.7 11.1
C 5.8 4.5 21.0 9.1
D 3.9 5.9 4.8 7.6
E 5.9 6.3 9.8 13.4
F 12.5 13.3 13.5 13.8
G 3.4 5.0 10.3 11.6
H 60.1 4.6 9.0 9.3
I 11.3 4.0 35.5 12.8
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reported that 10% noise-added data generated more than
25% of coefficient of variance in the dorsolateral prefrontal
cortex [9]. Considering the small size of the MS lesions,
the actual time-activity curves could be much noisier than
the aforementioned simulated 10% noise-added data. TheT1Gd
A) Gd(+), T2/Flair (+) , PET(+)
FLAIR
B) Gd(+), T2/Flair (+) , PET(-)
C) Gd(-), T2/Flair (+) , PET(-)
Figure 2 Typical MRI images and corresponding PET images for MRI-d
enhanced and high intensity in T2/FLAIR images and high uptake in PET im
lesion. (B) Gd-enhanced and high intensity in T2/FLAIR but not high uptak
but high intensity in T2/FLAIR and not high uptake in PET images.unstable estimation of the above outcome measures for
MS lesions might be in line with the results from the
simulation analysis.
Visual inspection of PET images
A previous PET TSPO study using [11C]PBR28 showed
high uptake in the white matter outside of the MRI-
defined MS lesions [3]. Some of the [11C]PBR28 high-
uptake areas developed to a new Gd-enhanced lesion
detected in the 1-month follow-up study. To detect such
a change, parametric images could be helpful. Although
an approach to de-noise the data in order to improve
the parametric images has been reported for [18F]
FEDAA1106 [18], the BPND images were not of sufficient
quality for visual inspection (i.e., diagnostic practice) due
to the low signal-to-noise ratio of [18F]FEDAA1106
BPND PET images.
Although SUV and VT images calculated by the Logan
plot were generated in this study, both SUV and VT
have some drawbacks for [18F]FEDAA1106. SUV values
did not always correspond to BPND or VT values. VT by
the Logan plot was reported to be underestimated com-
pared with VT by the 2TC model [9]. In both sets ofLogan VTSUV
efined MS lesions. There were three patterns as follows: (A) Gd-
ages. The images are from subject A. The arrow indicates the MS
e in PET images. The images are from subject D. (C) Not Gd-enhanced
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defined MS lesions, with the exception of one MS lesion
(Figure 2). In SUV and VT images, high nonspecific
uptake in the surrounding gray and white matter might
obscure the changes in the MS lesions and potential
changes outside of MS lesions.
The reason why one MS lesion showed high uptake,
while other MS lesions did not, could not be fully
explained. Although MS lesions might have different
features depending on their duration, the time span
between the MRI screening and the PET scan of the
patient with only MS lesion that showed high uptake
was 4 days, and this time span was not different from
the average 3.6-day-long time span of all the nine sub-
jects. The MS lesion was located in the right middle
cerebellar peduncle close to the brain surface facing the
cistern magna. This location could result in less signal
spillover and thereby higher contrast to the surrounding
tissues. Additionally, lesions, even though they are Gd-
enhancing, might still differ with respect to the histo-
logical characteristics as well as the respective content and
activation of microglia reflected by different amounts of
TSPO binding, but this could not be further evaluated in
our study.
The PET machine used in this study had a limited
spatial resolution, causing most of the MS lesions, which
are small, to be affected by a partial volume effect.
Higher-resolution PET machines might be an advantage
in investigating MS lesions in the future.
Conclusions
In conclusion, the present study does not endorse the
usefulness of [18F]FEDAA1106 as a PET radioligand for
the differentiation of patients with MS from healthy
controls or for the detection of active MS lesions in
patients. Even though information on the binding status
had been available, the radioligand still showed some
unfavorable kinetic characteristics, which would likely
hinder the further usage of it in a broader clinical
context. 18F radioligands with faster kinetics and lower
nonspecific binding than [18F]FEDAA1106 would have
greater potential for the evaluation of patients with MS.
Genetic information about TSPO binding must be taken
into account in future studies to allow patient stratification.
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